1 Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. GJ Dore, V Soriano, J Rockstroh, B Kupfer, E Tedaldi, L Peters, J Neuhaus, M Puoti, MB Klein, A Mocroft, B Clotet, JD Lundgren for the SMART INSIGHT study group.
AIDS 2010; 24:857-865. abstract
2 Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy. FC Lampe, DA Duprez, LH Kuller, R Tracy, J Otvos, E Stroes, DA Cooper, J Hoy, NI Paton, N Friis-Moller, J Neuhaus, AP Liappis, AN Phillips for the INSIGHT SMART Study Group.
J Acquir Immun Defic Synd 2010; 54(3):275-284.abstract
3 Smoking-related risk of all-cause mortality and serious clinical events among HIV-infected patients receiving highly active antiretroviral therapy in the Strategies for Management of Antiretroviral Therapy clinical trial. AR Lifson, et al.
Am J Pub Health 2010; Aug 19, 2010, epub ahead of print.abstract
4 The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters. E Martinez, F Visnegarwala, B Grund, A Thomas, C Gibert, J Shlay, F Drummond, D Pearce, S Edwards, P Reiss, W El-Sadr, A Carr for the INSIGHT SMART study group.
AIDS 2010; 24:353-363.abstract
5 Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. J Neuhaus, B Angus, JD Kowalska, A La Rosa, J Sampson, D Wentworth, A Mocroft for the INSIGHT SMART and ESPRIT study groups.
AIDS 2010; 24:697-706.abstract
6 Markers of inflammation, coagulation and renal function are elevated in adults with HIV infection. J Neuhaus, DR Jacobs Jr., JV Baker, A Calmy, D Duprez, A La Rosa, LH Kuller, SL Pett, M Ristola, MJ Ross, MG Shlipak, R Tracy, JD Neaton for the INSIGHT SMART, MESA and CARDIA Research Groups.
J Infect Dis 2010; 201(12):1788-1795.abstract
See also: Inflammation and complications of HIV disease. MP Dube, FR Sattler.(editorial)
J Infect Dis 2010; 201(12):1783-1785.
7 Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. EJ Wright, B Grund, K Robertson, BJ Brew, M Roediger, MP Bain, F Drummond, MJ Vjecha, J Hoy, C Miller, AC Penalva de Oliveira, W Pumpradit, JC Shlay, W El-Sadr, RW Price for the INSIGHT SMART Study Group.
Neurology 2010; Aug 11 (epub ahead of print). abstract
1 Lipoprotein particle subclasses, cardiovascular disease and HIV infection. DA Duprez, LH KulleR, R Tracy, J Otvos, DA Cooper, J Hoy, J Neuhaus, NI Paton, N Friis-Moller, F Lampe, AP Liappis, JD Neaton for the INSIGHT SMART Study Group.
Atherosclerosis 2009; 207(2):524-9. abstract
2 Relative risk of death in the SMART study (letter). B Grund, J Neuhaus, A Phillips for the INSIGHT SMART study group.
Lancet Infect Dis 2009; 9:724-5. abstract
3 Continuous antiretroviral therapy decreases bone mineral density. B Grund, G Peng, CL Gibert, JF Hoy, RL Isaksson, JC Shlay, E Martinez, P Reiss, F Visnegarwala, AD Carr for the INSIGHT SMART body composition substudy group.
AIDS 2009; 23:1519-1529. abstract
4 Interruption of antiretroviral therapy is associated with increased plasma cystatin. C.A Mocroft, C Wyatt, L Szczech, J Neuhaus, W El-Sadr, R Tracy, L Kuller, M Shlipak, B Angus, H Klinker, M Ross for the INSIGHT SMART study group.
AIDS 2009; 23:71-82. abstract
5 Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. AJ Rodger, Z Fox, JD Lundgren, LH Kuller, C Boesecke, D Gey, A Skoutelis, MB Goetz, AN Phillips for the INSIGHT SMART Study Group.
J Infect Dis 2009; 200(6):973-83. abstract
1 Episodic antiretroviral therapy increases HIV transmission risk compared with continuous therapy: results of a randomized controlled trial. W Burman, B Grund, J Neuhaus, J Douglas Jr, G Friedland, E Telzak, R Colebunders, N Paton, M Fisher, C Rietmeijer for the SMART Study Group and INSIGHT.
J Acquir Immun Defic Synd 2008; 49:142-150. abstract
2 The impact of episodic CD4 cell count-guided antiretroviral therapy on qualify of life. WJ Burman, B Grund, MP Roediger, G Friedland, J Darbyshire, AW Wu for the SMART Study Group.
J Acquir Immun Defic Synd 2008; 47(2):185-193. abstract
3 Asymptomatic myocardial ischaemia in HIV-infected adults. A Carr, B Grund, J Neuhaus, WM El-Sadr, G Grandits, C Gibert, RJ Prineas for the SMART Study Investigators.
AIDS 2008; 22(2):257-267. abstract
4 Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. Z Fox, A Phillips, C Cohen, J Neuhaus, J Baxter, S Emery, B Hirschel, K Huppler Hullsiek, C Stephan, JD Lundgren on behalf of the SMART Study Group.
AIDS 2008; 22:2279-2289. abstract
5 Pneumonia in HIV-Infected Persons: Increased Risk with Cigarette Smoking and Treatment Interruption.. FM Gordin, MP Roediger, PM Girard, JD Lundgren, JM Miro, A Palfreeman, MC Rodriguez-Barradas, MJ Wolff, PJ Easterbrook, K Clezy, LN Slater.
Am J Respir Crit Care Med. 2008 Jul 10. [Epub ahead of print] abstract
6 Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection. LH Kuller, R Tracy, W Belloso, SD Wit, F Drummond, HC Lane, B Ledergerber, J Lundgren, J Neuhaus, D Nixon, NI Paton, JD Neaton for the INSIGHT SMART Study Group.
PLoS Med. 2008 Oct 21;5(10):e203. abstract
7 Earlier initiation of antiretroviral therapy in treatment-naïve patients: implications of results of treatment interruption trials. JD Neaton, B Grund.
Current Opinion in HIV and AIDS 2008; 3:112-17. abstract
8 Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. AN Phillips, A Carr, J Neuhaus, F Visnegarwala, R Prineas, WJ Burman, I Williams, F Drummond, D Duprez, WH Belloso, FD Goebel, B Grund, A Hatzakis, J Vera, JD Lundgren.
Antivir Ther. 2008;13(2):177-87 abstract
9 The role of HIV in serious diseases other than AIDS. AN Phllips, J Neaton, JD Lundgren.
AIDS 2008; 22:2409-2418. abstract
10 Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, JD Lundgren, A Babiker, W El-Sadr, S Emery, B Grund, JD Neaton, J Neuhaus, AN Phillips.
J Infect Dis. 2008 Apr 15;197(8):1145-55 abstract
11 Risk for opportunistic disease and death after reinitiating continous antiretroviral therapy in patients with HIV previously receiving episodic therapy. A randomized trial. The SMART study group. Writing group: WM El-Sadr, B Grund, J Neuhaus, A Babiker, CJ Cohen, J Darbyshire, S Emery, JD Lundgren, A Phillips and JD Neaton.
Ann Intern Med. 2008;149:289-299. abstract
See also: Letter to Editor and Response. SK Gupta. (editorial)
Ann Int Med 2009; 1509(4):282-283.
12 Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. SMART Study Group.
J Infect Dis 2008; 197:1133-1144. abstract
See also: The search for data on when to start treatment for HIV infection. MD Hughes, HR Ribaudo. (editorial)
J Infect Dis 2008; 197:1084-1086.
13 Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. The SMART/INSIGHT and the D:A:D study groups. Writing committee: JD Lundgren, J Neuhaus, A Babiker, D Cooper, D Duprez, W El-Sadr, S Emery, F Gordin, J Kowalska, A Phillips, RJ Prineas, P Reiss, C Sabin, R Tracy, R Weber, B Grund and JD Neaton.
14 Determination of the underlying cause of death in three multicenter international HIV clinical trials. AR Lifson, WH Belloso, C Carey, RT Davey, D Duprez, WM El-Sadr, JM Gatell, DC Gey, JF HOy, EA KRum, R Nelson, DE Nixon, N Paton, C Pedersen, G Perez, RW PRice, RJ Prineas, FS Rhame, J Sampson, J Worley.
HIV Clin Trials 2008; 9:177-185 abstract
15 Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the Strategic Management of Antiretroviral Therapy (SMART) study. E Tedaldi, L Peters, J Neuhaus, M Puoti, J Rockstroh, MB Klein, GJ Dore, A Mocroft, V Soriano, B Clotet, JD Lundgren for the SMART Study Group and International Network for Strategic Initiatives in Global HIV Trials (INSIGHT).
Clin Infect Dis 2008; 47:1468-1475. abstract
See also: Hepatitis virus coinfection in the Strategic Management of Antiretroviral Therapy (SMART) study: A marker for nonliver, non-opportunistic disease mortality. DL Wyles. (editorial)
Clin Infect Dis 2008; epub 27 October.
1 Visceral and subcutaneous adiposity measurements in adults: Influence of measurement site.
KJ Ellis, B Grund, F Visnegarwala, L Thackeray, CG Miller, CE Chesson, W El-Sadr, and A Carr for the Strategies for Management of Anti-Retroviral Therapy (SMART) Study Group.
Obesity 2007; 15(6):1441-1447. abstract
2 Risk of cancers during interrupted antiretroviral therapy in the SMART study. MJ Silverberg, J Neuhaus, M Bower, D Gey, A Hatzakis, K Henry, J Hidalgo, L Lourtau, JD Neaton, G Tambussi, and DI Abrams.
AIDS. 2007, 21:1957-1963 abstract
1 CD4+ Count-Guided Interruption of Antiretroviral Treatment. The Strategies for Mangement of Antiretroviral Therapy (SMART) Study Group. Writing Group: WM El-Sadr, JD Lundgren, JD Neaton, F Gordin, D Abrams, RC Arduino, A Babiker, W Burman, N Clumeck, CJ Cohen, D Cohn, D Cooper, S Emery, G Fätkenheuer, B Gazzard, B Grund, J Hoy, K Klingman, M Losso, N Markowitz, J Neuhaus, AN Phillips, and C Rappoport.
N Engl J Med 2006; 355(22); 2283-2296 abstract
See also: Getting smarter - the toxicity of undertreated HIV infection. JS Currier, LR Baden. (editorial)
N Engl J Med 2006; 355:2359-2361.